Latest Headlines

Latest Headlines

Bristol-Myers lends Opdivo to a combo with Neon's neoantigen attack on cancer

A little more than two months after launching with a $55 million bankroll and a plan to develop next-gen cancer vaccines and immunotherapies, Third Rock startup Neon Therapeutics has allied with a leader in the checkpoint inhibitor space.

Bayer takes control of Compugen cancer program, pays out milestone

Bayer HealthCare has taken full control of the development of CGEN-15001T, an immune checkpoint inhibitor discovered by Compugen. The asset transfer triggered a $7.8 million (€7.1 million) milestone payment by Bayer, bringing the total pocketed by Compugen since it entered into the deal in 2013 up to $25 million.

Mitsubishi Tanabe backs Akebia PhIII with a $350M Asian deal for vadadustat

Three months after reassuring investors with upbeat Phase II data for its lead drug, Akebia has inked a $350 million Asian deal on the therapy, gaining a $40 million upfront and $60 million more in cash support for the pivotal study.

Unit of China's Yisheng Biopharma to work with U.S. Army on Ebola vaccine

The U.S. subsidiary of Beijing-based Yisheng Biopharma will work with the U.S. Army Medical Research Institute of Infectious Diseases to develop a new Ebola vaccine.

Medtronic, Samsung partner to develop neuromodulation implant apps for smart devices

Medtronic isn't exactly a consumer brand. But it's hoping that extending a partnership with Samsung will help it integrate its existing, extensive medical device portfolio with ubiquitous consumer smart devices. In June, the pair announced a partnership to do just that in diabetes and now they're expanding that deal into neuromodulation devices.

India lands $500M for vaccination program from Gavi alliance

Geneva-based Gavi, the global vaccine alliance funded by the Bill and Melinda Gates Foundation and other donors, has pledged $500 million over the next 5 years to support India's country-wide immunization program.

India's Sun Pharma signs up for neurological treatment deal

Sun Pharmaceutical of India has signed a deal with an institute in Israel and one in Spain to develop treatments for neurological diseases like strokes and the brain cancer glioblastoma.

Charles River digs into Parkinson's R&D with Fox Foundation in tow

CRO Charles River Laboratories has expanded its relationship with the Michael J. Fox Foundation for Parkinson's Research to investigate a promising target that could lead to new treatments for the disease.

China, New Zealand team up on health research program

Researchers in China and New Zealand have teamed up to develop a research program that will try to improve research initiatives "biomedicine, engineering sciences, and systems to support innovation and commercialization," according to a recent report.

WuXi and PRA Health amend ties in China

China's WuXi PharmaTech and North Carolina-based PRA Health Sciences said they have reorganized their joint operations in China, Hong Kong and Macau that were originally formed in 2013.